<DOC>
	<DOCNO>NCT02399033</DOCNO>
	<brief_summary>Study Objective : To evaluate efficacy safety Xihuang Capsules prevention recurrence patient hepatocellular carcinoma hepatectomy . Study Design : The study A Multicenter , Randomized , Controlled , Open-Label , Parallel-Group Clinical Trial . Patients randomly assign Xihuang Capsules group control group proportion 2 : 1 . The total sample size : 1000 case . Study Process : The study divide three phase : screening phase , treatment phase , follow-up phase.To complete screen two week , patient fit criterion randomly assign Xihuang Capsules group control group.In two week hepatectomy , Xihuang Capsules group receive Xihuang Capsules ( 2g , bid ) , Continuously take cancer recurrence death.Control group receive Xihuang Capsules . In first month three year treatment , Conducting visit every three month , evaluate efficacy safety hepatocellular carcinoma recurrence rate three year hepatectomy primary outcome . When enter follow-up phase , Keeping touch patient withdraw study clinic telephone follow-up every three month . From sign informed consent till end study , inspect adverse event concomitant medication subject visit .</brief_summary>
	<brief_title>Xihuang Capsules Prevention Recurrence Patients With Hepatocellular Carcinoma After Hepatectomy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Age : 2070 year old ; 2 . Gender : male female ; 3. clinical pathological diagnosis hepatocellular carcinoma ( HCC ) previously untreated patient ; 4 . The expected survival &gt; 3 month ; 5 . ChildPugh grade Alevel ; 6 . KPS score 50100 point ; 7 . In two week hepatectomy R0 resection surgery . Preoperative must meet following criterion : BCLC stage 0B ; conform indication hepatectomy ; Viable tumor resection confirm two highly qualified surgical doctor ; No surgical contraindication . 8. woman reproductive period must completely contraception 28 day treatment , treatment process 28 day treatment ; 9 . Men must completely contraception prohibit donation sperm donation treatment process 28 day treatment ; 10 . All patient must prohibit donation treatment process 28 day treatment ; 11 . In addition subject , prohibitting people take product . 12. patient good understanding could coordinate investigator trial . 13 . Patients enrol trial sign inform consent form , indicate understand purpose procedure trial , patient volunteer participate trial . 1 . Because suffer serious illness , laboratory abnormality mental abnormality , patient unable sign inform consent form ; 2. patient medical abnormality may result trial could evaluate security risk ; 3. person unable take oral drug . 4. coagulation dysfunction ; 5 . HIV , syphilisinfected person ; 6. person serious heart , liver renal failure ; 7. person know allergic drug component drug ; 8. person receive experimental therapy 28 day first treatment ; 9. person receive radiotherapy surgery ( include local surgery cancer treatment , eg . TACE ) addition hepatectomy 14 day first treatment ; 10. lactating pregnant woman ; 11. patient reproductive period unwilling unable contraception ; 12. person poor medication compliance ; 13 . The researcher consider unsuitable select patient .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Xihuang Capsules</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>Recurrence</keyword>
	<keyword>hepatectomy</keyword>
</DOC>